玻璃体内注射贝伐单抗治疗视网膜分支静脉阻塞继发的黄斑水肿。
Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion.
作者信息
Kreutzer T C, Alge C S, Wolf A H, Kook D, Burger J, Strauss R, Kunze C, Haritoglou C, Kampik A, Priglinger S
机构信息
Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Mathildenstr 8, 80336 Munich, Germany.
出版信息
Br J Ophthalmol. 2008 Mar;92(3):351-5. doi: 10.1136/bjo.2007.123513. Epub 2008 Jan 22.
PURPOSE
To evaluate the effect of intravitreal bevacizumab (Avastin) injections on visual acuity (VA) and foveal retinal thickness in patients with macular oedema secondary to branch retinal vein occlusion.
METHODS
A prospective, non-comparative, consecutive, interventional case series of 34 patients. Patients received repeated intravitreal injections of 1.25 mg bevacizumab. Main outcome measures were VA (Snellen charts and ETDRS) and retinal thickness (optical coherence tomography measurements) in a follow-up period of 6 months.
RESULTS
Patients presented at a mean age of 69 years (range 44-86). Mean duration of symptoms was 40 weeks (range 1-300). Mean (SD) VA at baseline was 0.79 (0.39) logMAR, improving to 0.51 (0.34) logMAR at 6 months (p = 0.009). Mean number of letters on the ETDRS chart at baseline was 45.3 (19.0), improving to 60.6 (19.9) at 6 months (p = 0.003). Mean (SD) retinal thickness at baseline was 474 (120) microm, declining to 316 (41) microm at 6 months.
CONCLUSION
Intravitreal injection of 1.25 mg bevacizumb appears to be an effective treatment option for branch retinal vein occlusion.
目的
评估玻璃体内注射贝伐单抗（阿瓦斯汀）对视网膜分支静脉阻塞继发黄斑水肿患者视力（VA）和黄斑视网膜厚度的影响。
方法
一项前瞻性、非对照、连续的介入性病例系列研究，共纳入34例患者。患者接受了1.25mg贝伐单抗的重复玻璃体内注射。主要观察指标为随访6个月期间的视力（Snellen视力表和ETDRS）和视网膜厚度（光学相干断层扫描测量）。
结果
患者的平均年龄为69岁（范围44 - 86岁）。症状的平均持续时间为40周（范围1 - 300周）。基线时平均（标准差）视力为0.79（0.39）logMAR，6个月时改善至0.51（0.34）logMAR（p = 0.009）。ETDRS视力表上基线时的平均字母数为45.3（19.0），6个月时改善至60.6（19.9）（p = 0.003）。基线时平均（标准差）视网膜厚度为474（120）微米，6个月时降至316（41）微米。
结论
玻璃体内注射1.25mg贝伐单抗似乎是视网膜分支静脉阻塞的一种有效治疗选择。
Zotero 插件